1, Kaveri Apartments, Near Meenakshi Cinema Flyover, Ramghat Road
Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms
Rantanen J, Khinast J
Can I get the benefits of Propionyl-L-Carnitine from food sources
GLP-1s drive the weight loss
12 AMS can progress to a potentially lethal illness, HACE, associated with neurological signs, such as truncal ataxia, altered mental status, depressed consciousness, and encephalopathy
